SynthesisMedicine2025
Impact of semaglutide use on glycemic and metabolic profile in adults with type 1 diabetes having overweight or obesity: A systematic review and meta-analysis.
Synthesis in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Glycemic Risk Across Exercise Modalities in Adults with Type 1 Diabetes Using Continuous Glucose Monitoring and Wearable Sensors: A Prospective Cohort Study.Journal of functional morphology and kinesiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSemaglutide is not yet approved for type 1 diabetes (T1D), but increasing evidence indicates it could offer clinical benefits for T1D patients, particularly those with overweight or obesity. Currently, no systematic review or meta-analysis has assessed semaglutide's effectiveness in adults with T1D with overweight or obesity; this systematic review and meta-analysis aims to fill that knowledge gap.
methodsElectronic databases were searched for articles on semaglutide use in adults with T1D with overweight or obesity. Co-primary outcomes were the percent changes in body weight and glycated hemoglobin from baseline; secondary outcomes were changes in total daily dose of insulin, glycemic variability, and adverse events. Statistical analysis was performed with RStudio software (Posit Software, PBC, Boston ), and results are presented as mean differences (MDs) along with 95% confidence intervals.
resultsData from 8 studies involving adults with T1D having overweight/obesity (N = 274, with diabetes duration ranging from 19.7 to 33 years) were analyzed. All studies had a low risk of bias. Semaglutide use was associated with reductions in body weight from baseline at 3 months (MD -3.27% [-6.07 to -0.47]), 6 months (MD -6.53% [-8.44 to -4.63]), and 12 months (MD -7.6% [-8.16 to -7.04]). There was also a reduction in glycated hemoglobin from baseline at 3 months (MD -0.54% [-0.62 to -0.46]), 6 months (MD -0.55% [-0.71 to -0.40]), and 12 months (MD -0.6% [-0.72 to -0.48]). Three months (MD -0.05 units/kg/d [-0.06 to -0.03]) and 6 months (MD -0.07 units/kg/d [-0.13 to -0.01]) but not 12 months (MD -0.00 units/kg/d [-0.06 to 0.05]) of semaglutide therapy were associated with a reduction in total daily dose of insulin. Time in range (MD 4.62% [0.85 to 8.39]) and time above range (MD -8.97% [-16.41 to -1.53]) improved after 3 months of semaglutide use. Adverse event data were scarce and mostly gastrointestinal.
conclusionIn adults with T1D having overweight or obesity, short-term semaglutide effectively promotes weight loss, improves glycemic control, and reduces insulin requirements. More long-term randomized controlled trials with a diverse group of participants are needed to incorporate semaglutide into the routine clinical management of these patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.